Adaptimmune Therapeutics Plc (ADAP) — Strategic Asset Allocation Index
Adaptimmune Therapeutics Plc (ADAP) has a Strategic Asset Allocation Index of 83.8% as of September 2023. Strategic assets (PP&E of $73.87 Million plus long-term investments of $-) total $73.87 Million, measured against net assets of $88.13 Million. A higher index reflects capital-intensive or investment-heavy strategies where strategic assets dominate the equity base. Check asset resilience ratio of Adaptimmune Therapeutics Plc to evaluate the company's liquid asset resilience ratio.
SAAI
Strategic Assets
PP&E
Net Assets
Adaptimmune Therapeutics Plc Strategic Asset Allocation Index (2013–2022)
This chart shows how Adaptimmune Therapeutics Plc's Strategic Asset Allocation Index has evolved across 10 annual periods from 2013 to 2022. As of September 2023, the index stands at 83.8%, representing strategic assets of $73.87 Million against net assets of $88.13 Million USD. See ADAP free cash flow debt coverage to measure the company's free cash flow as a share of total liabilities.
Annual Strategic Asset Allocation Index for Adaptimmune Therapeutics Plc (2013–2022)
The table below presents the year-by-year Strategic Asset Allocation Index for Adaptimmune Therapeutics Plc from 2013 to 2022, covering 10 annual filings. Each row shows PP&E, long-term investments, strategic assets combined, net assets, the index percentage, and the change in percentage points compared to the prior year. For the full company profile including market capitalisation, see Adaptimmune Therapeutics Plc market capitalisation.
| Year | SAAI | Strategic Assets (USD) | PP&E | LT Investments | Net Assets | Change (pp) |
|---|---|---|---|---|---|---|
| 2022 | 87.4% | $71.53 Million | $71.53 Million | $- | $81.88 Million | ▲ +72.6 pp |
| 2021 | 14.8% | $30.49 Million | $30.49 Million | $- | $205.96 Million | ▲ +6.7 pp |
| 2020 | 8.1% | $27.78 Million | $27.78 Million | $- | $341.23 Million | ▼ -17.0 pp |
| 2019 | 25.1% | $31.07 Million | $31.07 Million | $- | $123.64 Million | ▲ +10.5 pp |
| 2018 | 14.6% | $36.12 Million | $36.12 Million | $- | $246.88 Million | ▼ -5.4 pp |
| 2017 | 20.0% | $40.68 Million | $40.68 Million | $- | $202.98 Million | ▲ +3.2 pp |
| 2016 | 16.8% | $27.90 Million | $27.90 Million | $- | $166.14 Million | ▲ +11.7 pp |
| 2015 | 5.1% | $13.22 Million | $13.22 Million | $- | $259.61 Million | ▲ +3.0 pp |
| 2014 | 2.1% | $5.39 Million | $5.39 Million | $- | $259.61 Million | ▼ -57.5 pp |
| 2013 | 59.6% | $1.44 Million | $1.44 Million | $- | $2.41 Million | — |